Abstract. Hematopoietic lineage cell-specific protein 1 (HS1) is a 75-kDa intracellular protein that is expressed primarily in hematopoietic cells. Several previous studies have demonstrated the association between HS1 expression and a poor prognosis in hematopoietic malignancies; however, in solid tumors, no studies not been reported. The present study examined the distribution and expression of HS1 in human epithelial ovarian carcinoma (EOC) to determine its clinical significance. Paraffin sections were obtained from EOC tissues and immunostained with HS1 antibody, and then the staining intensities were evaluated. Overall survival (OS) was determined using the Kaplan-Meier estimator method, and multivariate analysis was performed using the Cox proportional hazards analysis. In total, 195 patients with EOC (median age, 56 years) were enrolled into the present study. HS1 immunoreactivity was categorized based on expression levels: Low (89/195; 45.6%) and high (106/195; 54.4%). Results demonstrated no association between expression level(s) and any clinicopathological parameter including age, International Federation of Gynecology and Obstetrics (FIGO) staging, type of chemotherapy or type of surgery received. The 5-year OS rates of patients who demonstrated low (n=89) and high (n=106) HS1 expression were 90.4 and 66.7%, respectively. The OS times for patients with high HS1 expression were significantly shorter compared with those for patients exhibiting low HS1 expression (P=0.0065). Results obtained from the multivariate analysis demonstrated that the FIGO stage and the amount of HS1 expressed were significant independent prognostic markers for poorer OS (hazard ratio, 3.539; 95% confidence interval, 1.221-12.811; P=0.0187). High HS1 expression levels may serve as a useful biomarker in patients with EOC who are likely to exhibit an unfavorable clinical outcome.
Introduction
Epithelial ovarian cancer (EOC) is the most lethal type of gynecological malignancy. In 2015, ~21,290 patients were diagnosed with EOC, and 14,180 succumbed to the disease in the USA (1) . Despite the majority of patients with EOC being asymptomatic in the early stages of the disease, this malignancy is frequently associated with multiple intraperitoneal disseminations and distant metastases (2) (3) (4) . Due to advances in therapeutic strategies, including the development of maximal cytoreductive surgery and several types of effective chemotherapy, it is possible to achieve clinical remission in patients with advanced epithelial ovarian cancer (5) . Furthermore, the short-term oncological outcome of women with EOC appears to be more favorable when compared with that of men; however, the majority of clinically complete responders experience disease recurrence (2, 3) .
Hematopoietic lineage cell-specific protein 1 (HS1) is a 75-kDa multi-domain protein that is primarily expressed within the hematopoietic lineage (6) (7) (8) . HS1 is frequently regarded as an F-actin binding protein that activates the actin-related protein-2/3 (Arp2/3) complex involved in cytoskeleton rearrangement (6) . HS1 is also a signal transducer that acts via the non-receptor-type tyrosine kinases of the Src family causing tyrosine residue phosphorylation (9) . Previous studies have demonstrated that HS1 is involved in cell growth, proliferation, adhesion and migration, such as B cells (10) , dendritic cells (11) , natural killer cells (12) , leukemic CLL cells (13) and leukemic B cells (8) that are involved in intracellular signaling. Furthermore, studies have identified that HS1 is expressed on platelets and natural killer cells, as well as in numerous types of hematological malignancies, including acute/chronic leukemia and B-cell chronic lymphocytic leukemia (CLL) (12, (14) (15) (16) .
As a hematopoietic homolog of cortactin, HS1 and cortactin demonstrate a marked similarity in their amino acid sequence and structure (17, 18 , TAKESHI SENGA 3 and FUMITAKA KIKKAWA and demonstrate F-actin binding through a 37-amino-acid repeat domain containing three and a half repeats of cortactin; the C-terminal of HS1 is highly homologous (86%) at the Src homology 3 domain (6, 17, 19) . Despite similarities in homology, HS1 and cortactin exert different biological functions. Cortactin is widely expressed in all types of cell and/or tissue with the exception of hematopoietic cells, and is associated with a poorer clinical prognosis in patients with different types of cancer including hepatocellular carcinoma, laryngeal cancer, ovarian cancer, colon cancer and non-small cell lung cancer (7, (20) (21) (22) (23) (24) (25) . However, to the best of our knowledge, there have been no studies investigating an association between HS1 expression and oncological outcome in solid tumors.
In the present study, the expression levels of HS1, and the potential association between HS1 expression and clinicopathological features in four common types (serous, clear cell, mucinous and endometrioid carcinoma) of EOC were investigated in patients with EOC.
Materials and methods
Patients and tissue samples. Tissues were obtained from 195 patients who underwent initial surgery at the Nagoya University Hospital (Nagoya, Aichi, Japan) between January 1999 and December 2011. Patients who underwent pre-surgical treatment including radiotherapy and chemotherapy, were excluded from the present study. All patients provided informed consent prior to recruitment. Surgical treatment consisted of total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymphadenectomy. In the situation where residual tumor remained, systemic lymphadenectomy was omitted. The histological type was assigned according to criteria outlined by the World Health Organization classification (2003) (26) . Clinical staging was reviewed based on staging criteria of the International Federation of Gynecology and Obstetrics 1988 (FIGO) (27) . All tissue samples were fixed in 10% neutral buffered formalin for 24 to 48 h at room temperature, embedded in paraffin and routinely stained with hematoxylin and eosin for histological examination.
Immunohistochemical HS1 staining and evaluation. Formalin-fixed, paraffin-embedded tissue blocks (4-µm thick) were mounted on charged glass slides, de-paraffinized, and rehydrated in a graded series of ethanol. Antigen retrieval was conducted in 10 mM citrate solution (pH 6.0) (Wako Pure Chemical Industries, Ltd., Osaka, Japan) at 98˚C for 15 min. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide for 5 min at room temperature. Blocking was performed in 10% normal goat serum (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA) with 0.025% Triton X-100 in Tris-buffered saline (TBS-T) for 60 min. Sections were treated with anti-HS1 rabbit monoclonal antibody in blocking buffer at 4˚C overnight (1:100; cat. no. 3890; Cell Signaling Technology, Inc., Danvers, MA, USA). Following three washes with TBS-T, sections were incubated with biotinylated goat anti-rabbit (1:200; cat. no. PK-4001; Vector Laboratories, Inc., Burlingame, CA, USA) horseradish peroxidase for 1 h and incubated with avidin-biotin complex reagent (cat. no. PK-4001; Vector Laboratories, Inc.) for 30 min at room temperature. Peroxidase activities were visualized using a 3,3'-diaminobenzidine peroxidase substrate kit (cat. no SK-4100; Vector Laboratories, Inc.). Slides were counterstained with Mayer's hematoxylin for 5 min at room temperature (Wako Pure Chemical Industries, Ltd.). Sections were dehydrated, cleared and mounted. Negative controls were run on all sections in blocking buffer without the primary antibody. The intensity of HS1 immunostaining was scored as follows: 0 (negative), 1 (weak), 2 (intermediate) and 3 (strong). The extent of staining was scored as 0 (0-25%), 1 (26-50%), 2 (51-75%) or 3 (>76%) according to the percentage of medium and strong staining in relation to the total cancer area. Specimens with a final staining score of 0 or 1 indicated low HS1 expression, whereas a final staining score of 2 or 3 indicated high HS1 expression. The scoring procedure was performed twice by two independent observers (each blinded to the other's scores) who had no knowledge of the patients' clinical parameters and other prognostic factors. The concordance rate was >95% between the observers. For the other 5% disagreement, it was adjusted by observer's consensus.
Statistical analysis. The χ
2 test was performed to analyze the association between low and high HS1 expression and patient clinicopathological parameters. Survival curves were generated using the Kaplan-Meier estimator method, which were then compared using the log-rank test. Overall survival (OS) was defined as the time between the date of initial therapy and the final follow-up or the time of patient mortality due to any cause. The prognostic significance of HS1 expression regarding other pathological variables was analyzed using univariate and multivariate Cox proportional hazards regression analysis. P<0.05 was considered to indicate a statistically significant difference.
Results

Patient characteristics.
In total, 195 patients with EOC were enrolled into the present study. The age range of diagnosed patients was between 20 and 82 years (median, 56 years). According to the results presented in Table I respectively. The OS time in patients with high HS1 expression was significantly shorter compared with that in patients with low HS1 expression (P= 0.0065; Fig. 2 ). Additionally, analysis of patients with a serous histological type revealed that significantly poorer OS was demonstrated in patients with high HS1 expression compared with that in patients with low HS1 expression (P= 0.0397; Fig. 3A) . Furthermore, analysis Immunoreactivity score, n (%) (Table IV) .
HS1 expression, n (%) -----------------------------------------------------------------
Discussion
To the best of our knowledge, the present study is the first to investigate and identify that HS1 is highly expressed in four representative types (serous, clear cell, mucinous and endometrioid carcinoma) of EOC samples, and that high expression is associated with a poor prognosis. van Rossum et al (19) reported that HS1 demonstrated a genomic organization similar to cortactin; however, the comparison between HS1 and cortactin levels in solid tumors is yet to be investigated.
It was previously hypothesized that HS1 and cortactin genes exhibit differing expression patterns; however, in platelets (28) and megakaryocytes (29) , cortactin is expressed similarly to HS1. In macrophages (30) and carcinoma cells (31), HS1 and cortactin are accumulated in podosomes. A recent study demonstrated that cortactin is highly expressed and regulates splicing in patients with B-cell CLL, and is associated with a poor prognosis (32) . These contradictory findings suggest that the HS1 gene may possess multiple functions due to being present in different pathological lineages.
Results from the present study demonstrated that HS1 was not expressed in normal ovarian tissue, and the positive expression rate in melanoma was high, with a staining score of 3 (data not shown). Xu et al (33) demonstrated that the aberrant expression of cortactin is associated with melanocytic tumor progression. In the present study HS1 expression was primarily identified in the cytoplasm of serous, clear cell, endometrioid and mucinous carcinoma cells. Additionally, results obtained from the Kaplan-Meier survival analysis indicated that high HS1 expression was significantly associated with a Figure 3 . (A) Kaplan-Meier overall survival curves for patients with serous EOC with regard to HS1 immunoexpression. The continuous line represents the low HS1 immunoexpression group (n=38), whereas the discontinuous line represents the high HS1 immunoexpression group (n=43). Patients with high HS1 expression demonstrated a significantly poorer overall survival rate compared with those with low HS1 expression (P= 0.0397). (B) Kaplan-Meier overall survival curves for patients with non-serous EOC with regard to HS1 immunoexpression. The continuous line represents the low HS1 immunoexpression group (n=51), whereas the discontinuous line represents the high HS1 immunoexpression group (n=63). Overall, patients with high HS1 expression demonstrated a poorer overall survival compared with those with low HS1 expression, although this difference was not significant (P= 0.0600). EOC, epithelial ovarian carcinoma; HS1, hematopoietic lineage cell-specific protein 1. Overall decreased survival rate compared with low HS1 expression. In total, ~80% of ovarian carcinoma samples were of the serous type, and results demonstrated that high HS1 expression was associated with a significant decrease in OS rate compared with low HS1 expression (34) . Furthermore, univariate analysis was performed in order to assess associations between prognosis and several clinical characteristics, including the FIGO stage, histological type, type of chemotherapy, type of surgery and HS1 expression level status. Results demonstrated that the advanced stage (stages III and IV), serous histological type, non-staging surgery and high expression of HS1 were significant prognostic markers for poor OS for patients with EOC. Multivariate analysis performed on these parameters using the Cox proportional hazards model revealed that high HS1 expression, EOC tumor type and the FIGO stage were independent prognostic factors for EOC. We hypothesize that HS1 functions similarly in serous and non-serous EOC; however, analysis of the association between OS and non-serous EOC could not be performed due to unbalanced stage distribution (in clear cell carcinoma, there were 47 stage I/II specimens (31 high vs. 16 low HS1 expression) and 13 stage III/IV specimens (10 high vs. 3 low HS1 expression). The unbalanced stage distribution may result in type II error (also known as a 'false negative' finding). We hypothesize that if a larger number of non-serous carcinoma specimens were reanalyzed, HS1 expression may be significantly associated with a poor prognosis.
A previous study demonstrated that HS1 was associated with the remodeling of the actin cytoskeleton (17). Scielzo et al (16) demonstrated that HS1 served important functions in cell migration, bone marrow infiltration and chemotherapy resistance, and therefore was associated with a poor prognosis. Additionally, it was identified that patients with B-cell CLL who exhibited the worst prognosis exhibited highly phosphorylated HS1 protein that was able to infiltrate the bone marrow (8) . In a previous animal model, silencing of HS1 expression exerted abnormal cell adhesion and reduced cell migration in immunodeficient mice (8) . HS1-deficient mice also demonstrated antigen-receptor-induced apoptosis and a proliferative response of splenic B and T cells (35) . Despite no direct evidence of HS1 expression in other types of solid carcinoma, several biomarkers associated with F-actin-bundling protein and anti-apoptosis, including cortactin, fascin and survivin, were expressed and associated with a poor prognosis in patients with EOC (23, 36) . A previous study demonstrated that fascin is upregulated in numerous types of human carcinoma, and is associated with tumor aggressiveness and poor OS (37) . Additionally, previous studies reported that cortactin and HS1 are actin-binding molecules involved in adhesion and cellular migration via actin skeleton remodeling in the majority of cell types (7, 17, 19, 20, 38) . Cortactin overexpression is associated with invasiveness of various solid tumor cells and a poor prognosis, such as human hepatocellular carcinoma (21), laryngeal carcinomas (22) , ovarian cancer (23), colon cancer (24) , non-small cell lung cancer (25) and hematopoietic lineages such as in platelets (28) , megakaryocytes (29) and B-cell CLL (32) . As HS1 is a homolog of cortactin, we hypothesized that HS1 may exhibit a similar role to cortactin with regard to its biological properties and mechanisms in EOC (17, 19) . Peritoneal metastasis is the most frequent clinical presentation demonstrated in EOC and is composed of multiple stages including release from the original ovarian neoplasm, attachment to the mesothelium and subsequent migration/invasion into the subperitoneal tissue. Future studies are required to investigate the underlying molecular mechanisms of HS1 in ovarian cancer metastasis.
In summary, the results of the present study demonstrate that HS1 is expressed in four common types of EOC and is associated with the OS of patients with EOC. Furthermore, to the best of our knowledge, this is the first report investigating the clinical significance of HS1 in EOC. The present study demonstrates that the immunoreactivity of HS1 is an independent prognostic marker for patients with EOC. In order to assess the role of the HS1 gene further, early clinical detection and novel therapeutic approaches are required in vivo and in vitro.
